An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.
A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
Abnormal protrusion of both eyes; may be caused by endocrine gland malfunction, malignancy, injury, or paralysis of the extrinsic muscles of the eye.
Bony cavity that holds the eyeball and its associated tissues and appendages.
The muscles that move the eye. Included in this group are the medial rectus, lateral rectus, superior rectus, inferior rectus, inferior oblique, superior oblique, musculus orbitalis, and levator palpebrae superioris.
Cell surface proteins that bind pituitary THYROTROPIN (also named thyroid stimulating hormone or TSH) and trigger intracellular changes of the target cells. TSH receptors are present in the nervous system and on target cells in the thyroid gland. Autoantibodies to TSH receptors are implicated in thyroid diseases such as GRAVES DISEASE and Hashimoto disease (THYROIDITIS, AUTOIMMUNE).
Autoantibodies that bind to the thyroid-stimulating hormone (TSH) receptor (RECEPTORS, THYROTROPIN) on thyroid epithelial cells. The autoantibodies mimic TSH causing an unregulated production of thyroid hormones characteristic of GRAVES DISEASE.
A visual symptom in which a single object is perceived by the visual cortex as two objects rather than one. Disorders associated with this condition include REFRACTIVE ERRORS; STRABISMUS; OCULOMOTOR NERVE DISEASES; TROCHLEAR NERVE DISEASES; ABDUCENS NERVE DISEASES; and diseases of the BRAIN STEM and OCCIPITAL LOBE.
Diseases affecting the eye.
Agents that are used to treat hyperthyroidism by reducing the excessive production of thyroid hormones.
A nonspecific tumor-like inflammatory lesion in the ORBIT of the eye. It is usually composed of mature LYMPHOCYTES; PLASMA CELLS; MACROPHAGES; LEUKOCYTES with varying degrees of FIBROSIS. Orbital pseudotumors are often associated with inflammation of the extraocular muscles (ORBITAL MYOSITIS) or inflammation of the lacrimal glands (DACRYOADENITIS).
A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.
A surgical operation for the relief of pressure in a body compartment or on a body part. (From Dorland, 28th ed)
A nonspecific term used to denote any cutaneous lesion or group of lesions, or eruptions of any type on the leg. (From Stedman, 25th ed)
Surgery performed on the eye or any of its parts.
Absent or reduced sensitivity to cutaneous stimulation.
A glycoprotein hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones (THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity.
The beta subunit of hexosaminidase A and hexosamininidase B. Mutations in the gene that encodes this protein are linked to SANDHOFF DISEASE and can result in loss of both hexosaminidase A activity and hexosaminidase B activity.
Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.
A PREDNISOLONE derivative with similar anti-inflammatory action.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
A highly vascularized endocrine gland consisting of two lobes joined by a thin band of tissue with one lobe on each side of the TRACHEA. It secretes THYROID HORMONES from the follicular cells and CALCITONIN from the parafollicular cells thereby regulating METABOLISM and CALCIUM level in blood, respectively.
Tissue that supports and binds other tissues. It consists of CONNECTIVE TISSUE CELLS embedded in a large amount of EXTRACELLULAR MATRIX.
The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.
Procedures of applying ENDOSCOPES for disease diagnosis and treatment. Endoscopy involves passing an optical instrument through a small incision in the skin i.e., percutaneous; or through a natural orifice and along natural body pathways such as the digestive tract; and/or through an incision in the wall of a tubular structure or organ, i.e. transluminal, to examine or perform surgery on the interior parts of the body.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
The organ of sight constituting a pair of globular organs made up of a three-layered roughly spherical structure specialized for receiving and responding to light.
A series of tests used to assess various functions of the eyes.
A condition characterized by a dry, waxy type of swelling (EDEMA) with abnormal deposits of MUCOPOLYSACCHARIDES in the SKIN and other tissues. It is caused by a deficiency of THYROID HORMONES. The skin becomes puffy around the eyes and on the cheeks. The face is dull and expressionless with thickened nose and lips.
Inflammatory diseases of the THYROID GLAND. Thyroiditis can be classified into acute (THYROIDITIS, SUPPURATIVE), subacute (granulomatous and lymphocytic), chronic fibrous (Riedel's), chronic lymphocytic (HASHIMOTO DISEASE), transient (POSTPARTUM THYROIDITIS), and other AUTOIMMUNE THYROIDITIS subtypes.
Chronic autoimmune thyroiditis, characterized by the presence of high serum thyroid AUTOANTIBODIES; GOITER; and HYPOTHYROIDISM.
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
Clarity or sharpness of OCULAR VISION or the ability of the eye to see fine details. Visual acuity depends on the functions of RETINA, neuronal transmission, and the interpretative ability of the brain. Normal visual acuity is expressed as 20/20 indicating that one can see at 20 feet what should normally be seen at that distance. Visual acuity can also be influenced by brightness, color, and contrast.

Childhood Graves' ophthalmopathy: results of a European questionnaire study. (1/179)

OBJECTIVE: Evaluation of the frequency of Graves' ophthalmopathy (GO) and its management in children and adolescents up to 18 years old with Graves' hyperthyroidism. STUDY DESIGN: This was a questionnaire study (QS) among members of the European Thyroid Association and the European Society for Paediatric Endocrinology. Approximately 300 QS were sent to members with electronic addresses and 110 QS were returned from 25 countries: 52 respondents said they had no experience with Graves' disease in this age group, but 67 respondents (23 paediatric and 44 adult endocrinologists) completed the QS. RESULTS: Out of 1963 patients with juvenile Graves' hyperthyroidism seen by respondents in the last 10 years, 641 (33%) had GO; about one-third of GO cases were < or =10 years old, and two-thirds were 11-18 years old. The prevalences of GO among juvenile Graves' hyperthyroidism were 36.6, 27.3 and 25.9% in countries in which the smoking prevalence among teenagers was > or =25, 20-25 and <20% respectively (P < 0.0001 by chi(2) test). When confronted with the standard case of a 13-year-old girl with Graves' hyperthyroidism and moderately severe active GO, the diagnostic approach included on average 4.9 biochemical tests (TSH, free thyroxine (FT(4)) and TSH.R-Ab, 100-88% of respondents) and 2.4 specific investigations (thyroid ultrasound by 69%, orthopsy/visual fields/visual acuity by 64% and orbital magnetic resonance imaging or computed tomography by 63%). Antithyroid drugs were the treatment of choice for 94% of respondents; 70% recommended a wait-and-see policy and 28% corticosteroids for the co-existing GO. In variants of the standard case, a younger age did not affect therapeutic approach very much. Recurrent hyperthyroidism would still be treated with antithyroid drugs by 66%, and with (131)I by 25%. Worsening of GO or active GO when euthyroid would convince about two-thirds of respondents to initiate treatment of GO, preferably with steroids. CONCLUSION: GO occurs in 33% of patients with juvenile Graves' hyperthyroidism; its prevalence is higher in countries with a higher prevalence of smoking among teenagers. The diagnostic approach to the standard case of a 13-year-old with Graves' hyperthyroidism and moderately severe active GO involves on average five biochemical tests; thyroid as well as orbital imaging is done in 84% of cases. Antithyroid drugs remain the treatment of choice for 94% of respondents, and even so in case of recurrences (66%). For GO, 70% recommend a wait-and-see policy; intervention, preferably with steroids, is advocated by two-thirds of respondents in cases of worsening or still-active eye disease despite euthyroidism.  (+info)

Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study. (2/179)

OBJECTIVE: To assess the efficacy and safety of combined orbital irradiation and systemic steroids in the management of moderate-to-severe Graves' ophthalmopathy. DESIGN: Single-blind randomised prospective study. SETTING: Regional hospital, Hong Kong. PATIENTS: Sixteen patients with active moderate-to-severe Graves' ophthalmopathy who were randomly assigned to steroid therapy (ST group) or combination therapy of orbital irradiation and systemic steroids (SRT group) between June 2000 and June 2003. MAIN OUTCOME MEASURES: NOSPECS scoring system, total eye score, subjective eye score, and extra-ocular muscle thickness as determined by either computed tomographic or magnetic resonance imaging scans. RESULTS: The study was completed by 15 of 16 patients. Both groups experienced improvement in total eye score, soft tissue swelling, ocular motility, visual acuity, and subjective eye score at 52-week follow-up. Total eye score improved earlier in the SRT group, achieving statistical significance (P<0.05) at as early as 4 weeks of follow-up. Improvement in ocular parameters was greater and led to a significantly greater reduction in total eye score than in the ST group at weeks 16, 24, and 52. Maximum extra-ocular muscle thickness was significantly reduced in the SRT group only. No change was observed in proptosis in either group. No serious adverse effect was observed with the addition of orbital irradiation to steroid therapy. CONCLUSION: A combination of orbital irradiation and systemic steroids is well tolerated and more effective than steroids alone in the treatment of active moderate-to-severe Graves' ophthalmopathy. It achieves greater and more rapid improvement in soft tissue swelling, ocular motility, and visual acuity.  (+info)

Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. (3/179)

PURPOSE: Graves' ophthalmopathy (GO) affects 50% to 60% of patients with Graves' hyperthyroidism, resulting in exophthalmos, periorbital edema, pain, double vision, optic neuropathy, and loss of vision. Fibroblasts are a key autoimmune target in GO and have effector functions that contribute to GO-associated pathologic conditions, including proliferation, production of excess glycosaminoglycans, and fat deposition. GO is also characterized by autoimmune inflammation of orbital connective tissue with mononuclear cell infiltration, including T cells. METHODS: To determine whether autologous T cells can drive proliferation of orbital fibroblasts and thus contribute to GO, a novel reverse autologous mixed-cell reaction (rAMCR) was performed. Fibroblasts cultured from orbital tissue of patients with GO that was removed during orbital decompression surgery were mixed with autologous T cells, and fibroblast proliferation was determined. RESULTS: Autologous T cells stimulated proliferation of orbital fibroblasts. Fibroblasts derived from blepharoplasty fat of two different patients did not proliferate, demonstrating that the effect is specific to cells derived from deep orbital fat. Proliferation was dependent on cell contact and on major histocompatibility complex (MHC) class II and CD40-CD154 (CD40 ligand) signaling. CONCLUSIONS: The results suggest that T cells and orbital fibroblasts participate in an antigen-dependent positive feedback loop in which presentation of autoantigens by fibroblasts via MHC class II and CD40-CD40L signaling results in T-cell activation. These activated T cells stimulate fibroblast proliferation, leading to fibroblast-associated diseases in GO. Thus, therapies that interfere with CD40-CD40L signaling, antigen expression by fibroblasts, or T-cell function may be effective in preventing progression of GO symptoms.  (+info)

Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease. (4/179)

Studies on thyrotropin receptor autoantibodies (TRAb) by measurement of both thyroid-stimulating antibodies (TSAb) and thyrotropin-binding inhibitory immunoglobulins (TBII) in serum from children with Graves' disease are limited in number of studies. The aim of this study was to investigate the levels of serum TSAb and TBII in children with Graves' disease, and to evaluate the clinical significance of these antibodies. We measured the serum TSAb and TBII at diagnosis and during management in 65 children with Graves' disease. Patients were divided into four groups according to their metabolic state: those with untreated active Graves' disease, those receiving treatment with antithyroid drugs, those in remission, and those in relapse. At diagnosis, both TSAb and TBII assays had high sensitivities and high specificities. In follow-up, the levels of both TSAb and TBII paralleled the course of the disease. There was a strong positive correlation between TSAb and TBII. TBII levels were significantly higher in the patients with ophthalmopathy than those without ophthalmopathy in untreated Graves' children. It was concluded that TSAb and TBII measurements are valuable in the diagnosis and management of children with Graves' disease.  (+info)

An infant case of Graves' disease with ophthalmopathy. (5/179)

Graves' disease is a rare disorder in children, particularly in infants. Ocular manifestations of Graves' disease in children are even more rare and are mild compared to adults. We report a 3-year-old girl with Graves' ophthalmopathy who visited our clinic because of lacrimation. Her family had also noticed exophthalmos, goiter, irritability and increased appetite for more than 3 months. The ophthalmologist noted bilateral proptosis, eyelid erythema, lacrimation, entropion of the lower eyelid, and superficial keratitis. Her serum concentrations of free thyroxine and free triiodothyronine were high, and thyroid-stimulating hormone (TSH) was low. Serum samples were markedly positive for antibodies to TSH receptor (TRAb) and thyroid-stimulating antibody (TSAb). Although hyperthyroidism was controlled with propylthiouracil within 3 weeks, her eye signs did not improve. We administered methylprednisolone pulse therapy for ophthalmopathy, but the effect was limited and the lacrimation due to entropion and superficial keratitis persisted. Titers of both TRAb and TSAb decreased slightly and transiently with the pulse therapy. One year later, both titers remained high and eye signs did not improve any more though she was clinically euthyroid. This might indicate that both TRAb and TSAb levels correlate with the clinical course. Therefore, TRAb or TSAb might be good indicators of progress of Graves' ophthalmopathy. Ocular manifestations of Graves' disease should be followed closely with measurements of both TRAb and TSAb even in infant cases.  (+info)

Euthyroid Graves' ophthalmopathy with negative autoantibodies. (6/179)

Graves' disease is an autoimmune-based hyperthyroidism in which a number of different antibodies directed against thyroid tissue plays a role. Graves' ophthalmopathy is thought to be a consequence of this autoimmune basis and occurs in some patients with Graves' disease. On occasional cases, the disease may present only with ophthalmopathy without hyperthyroidism. A 32-year-old woman with euthyroid Graves' ophthalmopathy and negative thyroid autoantibodies, including TSH receptor antibody, is presented here.  (+info)

Graves' disease and Hashimoto's thyroiditis in monozygotic twins: case study as well as transcriptomic and immunohistological analysis of thyroid tissues. (7/179)

OBJECTIVE: To report on the rare simultaneous occurrence of Graves' disease (GD) and Hashimoto's thyroiditis (HT) in monozygotic twins. DESIGN: We compared the pattern of thyroid tissue-derived cDNAs to gain insight into previous and ongoing immune destruction and reconstruction processes using microarrays. The results were confirmed by immunohistology and real-time PCR. RESULTS: Destruction of thyroid tissue in HT reduced levels of thyrocyte-related cDNAs and cDNAs encoding extracellular matrix components, but increased levels of proteases involved in extracellular matrix degradation compared with GD. Lymphocytic infiltrates forming ectopic follicles replaced the thyroid tissue almost completely in HT. Thus, lymphocyte-related cDNA levels were higher in HT than in GD. The same was true for many chemokines and their receptors, which not only enable migration towards the thyroid but also maintain the lymphocytic infiltrate. HT also showed increased levels of cDNAs encoding molecules related to apoptosis than did GD. Surprisingly, the Th1- and Th2-specific cytokine profiles suggested for HT and GD respectively could not be confirmed. cDNAs encoding factors and receptors involved in angiogenesis were increased in GD compared with HT. CONCLUSIONS: Comparison of gene expression reflects the cellular differences between the two types of autoimmune thyroid disease in twins with identical genetic and similar environmental background.  (+info)

Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves' disease. (8/179)

Little is known about the immunosuppressive effect of glucocorticoids on TSH receptor antibodies. We observed the long-term prognosis and serum TSH binding inhibitor immunoglobulin (TBII) levels in patients with Graves' ophthalmopathy who had received intravenous methylprednisolone pulse therapy (pulse therapy) followed by oral prednisolone administration in order to ascertain how long the immunosuppressive effect of glucocorticoids continued. This is the first report on the effect of pulse therapy on Graves' disease outcome. We observed 67 patients who were treated by antithyroid drugs (ATD) alone for 2 years after pulse therapy. TBII was evaluated before and 3, 6, 12, 18, and 24 months after pulse therapy. The mean TBII decreased significantly 3 months after pulse therapy (p<0.001), and was maintained until 24 months. There were 24 patients whose TBII was positive (>15%) at 24 months, in whom the mean TBII decreased significantly 3 to 6 months after pulse therapy (p<0.001), but increased again at 12 to 24 months (p<0.05). Thus, the immunosuppressive effect of glucocorticoids may be lost at 12 months after pulse therapy in these patients. The remission rate in the pulse therapy group was 40.98%, and that of the control patient group was 48.57%. There was no significant difference between the two. These results suggest that the immunosuppressive effect of pulse therapy was temporary, and that pulse therapy did not increase remission rate of Graves' disease.  (+info)

Graves' ophthalmopathy, also known as Graves' eye disease or thyroid eye disease, is an autoimmune condition that affects the eyes. It often occurs in individuals with Graves' disease, an autoimmune disorder that causes hyperthyroidism (overactive thyroid gland). However, it can also occur in people without Graves' disease.

In Graves' ophthalmopathy, the immune system attacks the tissue behind the eyes, causing inflammation and enlargement of the muscles, fatty tissue, and connective tissue within the orbit (eye socket). This leads to symptoms such as:

1. Protrusion or bulging of the eyes (exophthalmos)
2. Redness and swelling of the eyelids
3. Double vision (diplopia) due to restricted eye movement
4. Pain and discomfort, especially when looking up, down, or sideways
5. Light sensitivity (photophobia)
6. Tearing and dryness in the eyes
7. Vision loss in severe cases

The treatment for Graves' ophthalmopathy depends on the severity of the symptoms and may include medications to manage inflammation, eye drops or ointments for dryness, prisms to correct double vision, or surgery for severe cases.

Graves' disease is defined as an autoimmune disorder that leads to overactivity of the thyroid gland (hyperthyroidism). It results when the immune system produces antibodies that stimulate the thyroid gland, causing it to produce too much thyroid hormone. This can result in a variety of symptoms such as rapid heartbeat, weight loss, heat intolerance, and bulging eyes (Graves' ophthalmopathy). The exact cause of Graves' disease is unknown, but it is more common in women and people with a family history of the disorder. Treatment may include medications to control hyperthyroidism, radioactive iodine therapy to destroy thyroid tissue, or surgery to remove the thyroid gland.

Exophthalmos is a medical condition that refers to the abnormal protrusion or bulging of one or both eyes beyond the normal orbit (eye socket). This condition is also known as proptosis. Exophthalmos can be caused by various factors, including thyroid eye disease (Graves' ophthalmopathy), tumors, inflammation, trauma, or congenital abnormalities. It can lead to various symptoms such as double vision, eye discomfort, redness, and difficulty closing the eyes. Treatment of exophthalmos depends on the underlying cause and may include medications, surgery, or radiation therapy.

In medical terms, the orbit refers to the bony cavity or socket in the skull that contains and protects the eye (eyeball) and its associated structures, including muscles, nerves, blood vessels, fat, and the lacrimal gland. The orbit is made up of several bones: the frontal bone, sphenoid bone, zygomatic bone, maxilla bone, and palatine bone. These bones form a pyramid-like shape that provides protection for the eye while also allowing for a range of movements.

The oculomotor muscles are a group of extraocular muscles that control the movements of the eye. They include:

1. Superior rectus: This muscle is responsible for elevating the eye and helping with inward rotation (intorsion) when looking downwards.
2. Inferior rectus: It depresses the eye and helps with outward rotation (extorsion) when looking upwards.
3. Medial rectus: This muscle adducts, or moves, the eye towards the midline of the face.
4. Inferior oblique: The inferior oblique muscle intorts and elevates the eye.
5. Superior oblique: It extorts and depresses the eye.

These muscles work together to allow for smooth and precise movements of the eyes, enabling tasks such as tracking moving objects, reading, and maintaining visual fixation on a single point in space.

Thyrotropin receptors (TSHRs) are a type of G protein-coupled receptor found on the surface of cells in the thyroid gland. They bind to thyroid-stimulating hormone (TSH), which is produced and released by the pituitary gland. When TSH binds to the TSHR, it activates a series of intracellular signaling pathways that stimulate the production and release of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). These hormones are important for regulating metabolism, growth, and development in the body. Mutations in the TSHR gene can lead to various thyroid disorders, such as hyperthyroidism or hypothyroidism.

Immunoglobulins, Thyroid-Stimulating (TSI), are autoantibodies that bind to the thyroid-stimulating hormone receptor (TSHR) on the surface of thyroid cells. These antibodies mimic the action of TSH and stimulate the growth and function of the thyroid gland, leading to excessive production of thyroid hormones. This results in a condition known as Graves' disease, which is characterized by hyperthyroidism, goiter, and sometimes ophthalmopathy (eye problems). The presence and titer of TSIs are used in the diagnosis of Graves' disease.

Diplopia is a medical term that refers to the condition where a person sees two images of a single object. It is commonly known as double vision. This can occur due to various reasons, such as nerve damage or misalignment of the eyes. Diplopia can be temporary or chronic and can affect one or both eyes. If you're experiencing diplopia, it's essential to consult an eye care professional for proper evaluation and treatment.

Eye diseases are a range of conditions that affect the eye or visual system, causing damage to vision and, in some cases, leading to blindness. These diseases can be categorized into various types, including:

1. Refractive errors: These include myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia, which affect the way light is focused on the retina and can usually be corrected with glasses or contact lenses.
2. Cataracts: A clouding of the lens inside the eye that leads to blurry vision, glare, and decreased contrast sensitivity. Cataract surgery is the most common treatment for this condition.
3. Glaucoma: A group of diseases characterized by increased pressure in the eye, leading to damage to the optic nerve and potential blindness if left untreated. Treatment includes medications, laser therapy, or surgery.
4. Age-related macular degeneration (AMD): A progressive condition that affects the central part of the retina called the macula, causing blurry vision and, in advanced stages, loss of central vision. Treatment may include anti-VEGF injections, laser therapy, or nutritional supplements.
5. Diabetic retinopathy: A complication of diabetes that affects the blood vessels in the retina, leading to bleeding, leakage, and potential blindness if left untreated. Treatment includes laser therapy, anti-VEGF injections, or surgery.
6. Retinal detachment: A separation of the retina from its underlying tissue, which can lead to vision loss if not treated promptly with surgery.
7. Amblyopia (lazy eye): A condition where one eye does not develop normal vision, often due to a misalignment or refractive error in childhood. Treatment includes correcting the underlying problem and encouraging the use of the weaker eye through patching or other methods.
8. Strabismus (crossed eyes): A misalignment of the eyes that can lead to amblyopia if not treated promptly with surgery, glasses, or other methods.
9. Corneal diseases: Conditions that affect the transparent outer layer of the eye, such as keratoconus, Fuchs' dystrophy, and infectious keratitis, which can lead to vision loss if not treated promptly.
10. Uveitis: Inflammation of the middle layer of the eye, which can cause vision loss if not treated promptly with anti-inflammatory medications or surgery.

Antithyroid agents are a class of medications that are used to treat hyperthyroidism, a condition in which the thyroid gland produces too much thyroid hormone. These medications work by inhibiting the production of thyroid hormones in the thyroid gland. There are several types of antithyroid agents available, including:

1. Propylthiouracil (PTU): This medication works by blocking the enzyme that is needed to produce thyroid hormones. It also reduces the conversion of thyroxine (T4) to triiodothyronine (T3), another thyroid hormone, in peripheral tissues.
2. Methimazole: This medication works similarly to propylthiouracil by blocking the enzyme that is needed to produce thyroid hormones. However, it does not affect the conversion of T4 to T3 in peripheral tissues.
3. Carbimazole: This medication is converted to methimazole in the body and works similarly to block the production of thyroid hormones.

Antithyroid agents are usually taken orally, and their effects on thyroid hormone production begin within a few hours after ingestion. However, it may take several weeks for patients to notice an improvement in their symptoms. These medications can have side effects, including rash, hives, and joint pain. In rare cases, they can cause liver damage or agranulocytosis, a condition in which the body does not produce enough white blood cells.

It is important to note that antithyroid agents do not cure hyperthyroidism; they only treat the symptoms by reducing thyroid hormone production. Therefore, patients may need to take these medications for several months or even years, depending on their individual circumstances. In some cases, surgery or radioactive iodine therapy may be recommended as alternative treatments for hyperthyroidism.

Orbital pseudotumor, also known as orbital inflammatory syndrome or idiopathic orbital inflammation, is a non-specific term used to describe a group of conditions characterized by inflammation in the orbit (the bony cavity surrounding the eye) without any identifiable cause. It is not a true tumor, but rather an inflammatory reaction that can mimic the symptoms and signs of a tumor.

The condition can affect people of any age, although it is more common in middle-aged adults. The exact cause of orbital pseudotumor is unknown, but it is believed to be related to an abnormal immune response or inflammation triggered by various factors such as infections, trauma, or autoimmune disorders.

Symptoms of orbital pseudotumor may include eye pain, redness, swelling, protrusion of the eyeball (proptosis), double vision, and decreased vision. Diagnostic tests such as imaging studies (CT or MRI scans) and biopsy may be used to rule out other causes of orbital inflammation. Treatment typically involves corticosteroids to reduce inflammation, although other immunosuppressive medications may be necessary in severe cases. In some cases, the condition may resolve on its own without treatment.

Methimazole is an anti-thyroid medication that is primarily used to treat hyperthyroidism, a condition in which the thyroid gland produces excessive amounts of thyroid hormones. It works by inhibiting the enzyme thyroperoxidase, which is essential for the production of thyroid hormones. By blocking this enzyme, methimazole reduces the amount of thyroid hormones produced by the thyroid gland, helping to restore normal thyroid function.

Methimazole is available in oral tablet form and is typically taken two to three times a day. Common side effects of methimazole include nausea, vomiting, skin rashes, and joint pain. In rare cases, it can cause more serious side effects such as liver damage or agranulocytosis (a severe decrease in white blood cell count).

It is important to note that methimazole should only be used under the close supervision of a healthcare provider, as regular monitoring of thyroid function and potential side effects is necessary. Additionally, it may take several weeks or months of treatment with methimazole before thyroid function returns to normal.

Surgical decompression is a medical procedure that involves relieving pressure on a nerve or tissue by creating additional space. This is typically accomplished through the removal of a portion of bone or other tissue that is causing the compression. The goal of surgical decompression is to alleviate symptoms such as pain, numbness, tingling, or weakness caused by the compression.

In the context of spinal disorders, surgical decompression is often used to treat conditions such as herniated discs, spinal stenosis, or bone spurs that are compressing nerves in the spine. The specific procedure used may vary depending on the location and severity of the compression, but common techniques include laminectomy, discectomy, and foraminotomy.

It's important to note that surgical decompression is a significant medical intervention that carries risks such as infection, bleeding, and injury to surrounding tissues. As with any surgery, it should be considered as a last resort after other conservative treatments have been tried and found to be ineffective. A thorough evaluation by a qualified medical professional is necessary to determine whether surgical decompression is appropriate in a given case.

Leg dermatoses is a general term that refers to various skin conditions affecting the legs. This can include a wide range of inflammatory, infectious, or degenerative diseases that cause symptoms such as redness, itching, scaling, blistering, or pigmentation changes on the leg skin. Examples of specific leg dermatoses include stasis dermatitis, venous eczema, contact dermatitis, lichen planus, psoriasis, and cellulitis among others. Accurate diagnosis usually requires a thorough examination and sometimes a biopsy to determine the specific type of dermatosis and appropriate treatment.

Ophthalmologic surgical procedures refer to various types of surgeries performed on the eye and its surrounding structures by trained medical professionals called ophthalmologists. These procedures aim to correct or improve vision, diagnose and treat eye diseases or injuries, and enhance the overall health and functionality of the eye. Some common examples of ophthalmologic surgical procedures include:

1. Cataract Surgery: This procedure involves removing a cloudy lens (cataract) from the eye and replacing it with an artificial intraocular lens (IOL).
2. LASIK (Laser-Assisted In Situ Keratomileusis): A type of refractive surgery that uses a laser to reshape the cornea, correcting nearsightedness, farsightedness, and astigmatism.
3. Glaucoma Surgery: Several surgical options are available for treating glaucoma, including laser trabeculoplasty, traditional trabeculectomy, and various drainage device implantations. These procedures aim to reduce intraocular pressure (IOP) and prevent further optic nerve damage.
4. Corneal Transplant: This procedure involves replacing a damaged or diseased cornea with a healthy donor cornea to restore vision and improve the eye's appearance.
5. Vitreoretinal Surgery: These procedures focus on treating issues within the vitreous humor (gel-like substance filling the eye) and the retina, such as retinal detachment, macular holes, or diabetic retinopathy.
6. Strabismus Surgery: This procedure aims to correct misalignment of the eyes (strabismus) by adjusting the muscles responsible for eye movement.
7. Oculoplastic Surgery: These procedures involve reconstructive, cosmetic, and functional surgeries around the eye, such as eyelid repair, removal of tumors, or orbital fracture repairs.
8. Pediatric Ophthalmologic Procedures: Various surgical interventions are performed on children to treat conditions like congenital cataracts, amblyopia (lazy eye), or blocked tear ducts.

These are just a few examples of ophthalmic surgical procedures. The specific treatment plan will depend on the individual's condition and overall health.

Hyperesthesia is a medical term that refers to an increased sensitivity to sensory stimuli, including touch, pain, or temperature. It can affect various parts of the body and can be caused by different conditions, such as nerve damage, multiple sclerosis, or complex regional pain syndrome. Hyperesthesia can manifest as a heightened awareness of sensations, which can be painful or uncomfortable, and may interfere with daily activities. It is essential to consult a healthcare professional for an accurate diagnosis and appropriate treatment if experiencing symptoms of hyperesthesia.

Thyrotropin, also known as thyroid-stimulating hormone (TSH), is a hormone secreted by the anterior pituitary gland. Its primary function is to regulate the production and release of thyroxine (T4) and triiodothyronine (T3) hormones from the thyroid gland. Thyrotropin binds to receptors on the surface of thyroid follicular cells, stimulating the uptake of iodide and the synthesis and release of T4 and T3. The secretion of thyrotropin is controlled by the hypothalamic-pituitary-thyroid axis: thyrotropin-releasing hormone (TRH) from the hypothalamus stimulates the release of thyrotropin, while T3 and T4 inhibit its release through a negative feedback mechanism.

Beta-Hexosaminidase beta chain is a subunit of the beta-Hexosaminidase enzyme, which is responsible for breaking down complex lipids called gangliosides in the body. Specifically, it helps to break down a type of ganglioside called GM2 ganglioside into simpler components. Defects in this enzyme can lead to a group of genetic disorders known as the GM2 gangliosidoses, which include Tay-Sachs disease and Sandhoff disease. These conditions are characterized by the accumulation of GM2 gangliosides in various tissues, particularly in the nervous system, leading to progressive neurological deterioration.

Optic nerve diseases refer to a group of conditions that affect the optic nerve, which transmits visual information from the eye to the brain. These diseases can cause various symptoms such as vision loss, decreased visual acuity, changes in color vision, and visual field defects. Examples of optic nerve diseases include optic neuritis (inflammation of the optic nerve), glaucoma (damage to the optic nerve due to high eye pressure), optic nerve damage from trauma or injury, ischemic optic neuropathy (lack of blood flow to the optic nerve), and optic nerve tumors. Treatment for optic nerve diseases varies depending on the specific condition and may include medications, surgery, or lifestyle changes.

Methylprednisolone is a synthetic glucocorticoid drug, which is a class of hormones that naturally occur in the body and are produced by the adrenal gland. It is often used to treat various medical conditions such as inflammation, allergies, and autoimmune disorders. Methylprednisolone works by reducing the activity of the immune system, which helps to reduce symptoms such as swelling, pain, and redness.

Methylprednisolone is available in several forms, including tablets, oral suspension, and injectable solutions. It may be used for short-term or long-term treatment, depending on the condition being treated. Common side effects of methylprednisolone include increased appetite, weight gain, insomnia, mood changes, and increased susceptibility to infections. Long-term use of methylprednisolone can lead to more serious side effects such as osteoporosis, cataracts, and adrenal suppression.

It is important to note that methylprednisolone should be used under the close supervision of a healthcare provider, as it can cause serious side effects if not used properly. The dosage and duration of treatment will depend on various factors such as the patient's age, weight, medical history, and the condition being treated.

Autoantibodies are defined as antibodies that are produced by the immune system and target the body's own cells, tissues, or organs. These antibodies mistakenly identify certain proteins or molecules in the body as foreign invaders and attack them, leading to an autoimmune response. Autoantibodies can be found in various autoimmune diseases such as rheumatoid arthritis, lupus, and thyroiditis. The presence of autoantibodies can also be used as a diagnostic marker for certain conditions.

The thyroid gland is a major endocrine gland located in the neck, anterior to the trachea and extends from the lower third of the Adams apple to the suprasternal notch. It has two lateral lobes, connected by an isthmus, and sometimes a pyramidal lobe. This gland plays a crucial role in the metabolism, growth, and development of the human body through the production of thyroid hormones (triiodothyronine/T3 and thyroxine/T4) and calcitonin. The thyroid hormones regulate body temperature, heart rate, and the production of protein, while calcitonin helps in controlling calcium levels in the blood. The function of the thyroid gland is controlled by the hypothalamus and pituitary gland through the thyroid-stimulating hormone (TSH).

Connective tissue is a type of biological tissue that provides support, strength, and protection to various structures in the body. It is composed of cells called fibroblasts, which produce extracellular matrix components such as collagen, elastin, and proteoglycans. These components give connective tissue its unique properties, including tensile strength, elasticity, and resistance to compression.

There are several types of connective tissue in the body, each with its own specific functions and characteristics. Some examples include:

1. Loose or Areolar Connective Tissue: This type of connective tissue is found throughout the body and provides cushioning and support to organs and other structures. It contains a large amount of ground substance, which allows for the movement and gliding of adjacent tissues.
2. Dense Connective Tissue: This type of connective tissue has a higher concentration of collagen fibers than loose connective tissue, making it stronger and less flexible. Dense connective tissue can be further divided into two categories: regular (or parallel) and irregular. Regular dense connective tissue, such as tendons and ligaments, has collagen fibers that run parallel to each other, providing great tensile strength. Irregular dense connective tissue, such as the dermis of the skin, has collagen fibers arranged in a more haphazard pattern, providing support and flexibility.
3. Adipose Tissue: This type of connective tissue is primarily composed of fat cells called adipocytes. Adipose tissue serves as an energy storage reservoir and provides insulation and cushioning to the body.
4. Cartilage: A firm, flexible type of connective tissue that contains chondrocytes within a matrix of collagen and proteoglycans. Cartilage is found in various parts of the body, including the joints, nose, ears, and trachea.
5. Bone: A specialized form of connective tissue that consists of an organic matrix (mainly collagen) and an inorganic mineral component (hydroxyapatite). Bone provides structural support to the body and serves as a reservoir for calcium and phosphate ions.
6. Blood: Although not traditionally considered connective tissue, blood does contain elements of connective tissue, such as plasma proteins and leukocytes (white blood cells). Blood transports nutrients, oxygen, hormones, and waste products throughout the body.

Thyroxine (T4) is a type of hormone produced and released by the thyroid gland, a small butterfly-shaped endocrine gland located in the front of your neck. It is one of two major hormones produced by the thyroid gland, with the other being triiodothyronine (T3).

Thyroxine plays a crucial role in regulating various metabolic processes in the body, including growth, development, and energy expenditure. Specifically, T4 helps to control the rate at which your body burns calories for energy, regulates protein, fat, and carbohydrate metabolism, and influences the body's sensitivity to other hormones.

T4 is produced by combining iodine and tyrosine, an amino acid found in many foods. Once produced, T4 circulates in the bloodstream and gets converted into its active form, T3, in various tissues throughout the body. Thyroxine has a longer half-life than T3, which means it remains active in the body for a more extended period.

Abnormal levels of thyroxine can lead to various medical conditions, such as hypothyroidism (underactive thyroid) or hyperthyroidism (overactive thyroid). These conditions can cause a range of symptoms, including weight gain or loss, fatigue, mood changes, and changes in heart rate and blood pressure.

Fibroblasts are specialized cells that play a critical role in the body's immune response and wound healing process. They are responsible for producing and maintaining the extracellular matrix (ECM), which is the non-cellular component present within all tissues and organs, providing structural support and biochemical signals for surrounding cells.

Fibroblasts produce various ECM proteins such as collagens, elastin, fibronectin, and laminins, forming a complex network of fibers that give tissues their strength and flexibility. They also help in the regulation of tissue homeostasis by controlling the turnover of ECM components through the process of remodeling.

In response to injury or infection, fibroblasts become activated and start to proliferate rapidly, migrating towards the site of damage. Here, they participate in the inflammatory response, releasing cytokines and chemokines that attract immune cells to the area. Additionally, they deposit new ECM components to help repair the damaged tissue and restore its functionality.

Dysregulation of fibroblast activity has been implicated in several pathological conditions, including fibrosis (excessive scarring), cancer (where they can contribute to tumor growth and progression), and autoimmune diseases (such as rheumatoid arthritis).

Endoscopy is a medical procedure that involves the use of an endoscope, which is a flexible tube with a light and camera at the end, to examine the interior of a body cavity or organ. The endoscope is inserted through a natural opening in the body, such as the mouth or anus, or through a small incision. The images captured by the camera are transmitted to a monitor, allowing the physician to visualize the internal structures and detect any abnormalities, such as inflammation, ulcers, or tumors. Endoscopy can also be used for diagnostic purposes, such as taking tissue samples for biopsy, or for therapeutic purposes, such as removing polyps or performing minimally invasive surgeries.

Iodine radioisotopes are radioactive isotopes of the element iodine, which decays and emits radiation in the form of gamma rays. Some commonly used iodine radioisotopes include I-123, I-125, I-131. These radioisotopes have various medical applications such as in diagnostic imaging, therapy for thyroid disorders, and cancer treatment.

For example, I-131 is commonly used to treat hyperthyroidism and differentiated thyroid cancer due to its ability to destroy thyroid tissue. On the other hand, I-123 is often used in nuclear medicine scans of the thyroid gland because it emits gamma rays that can be detected by a gamma camera, allowing for detailed images of the gland's structure and function.

It is important to note that handling and administering radioisotopes require specialized training and safety precautions due to their radiation-emitting properties.

The eye is the organ of sight, primarily responsible for detecting and focusing on visual stimuli. It is a complex structure composed of various parts that work together to enable vision. Here are some of the main components of the eye:

1. Cornea: The clear front part of the eye that refracts light entering the eye and protects the eye from harmful particles and microorganisms.
2. Iris: The colored part of the eye that controls the amount of light reaching the retina by adjusting the size of the pupil.
3. Pupil: The opening in the center of the iris that allows light to enter the eye.
4. Lens: A biconvex structure located behind the iris that further refracts light and focuses it onto the retina.
5. Retina: A layer of light-sensitive cells (rods and cones) at the back of the eye that convert light into electrical signals, which are then transmitted to the brain via the optic nerve.
6. Optic Nerve: The nerve that carries visual information from the retina to the brain.
7. Vitreous: A clear, gel-like substance that fills the space between the lens and the retina, providing structural support to the eye.
8. Conjunctiva: A thin, transparent membrane that covers the front of the eye and the inner surface of the eyelids.
9. Extraocular Muscles: Six muscles that control the movement of the eye, allowing for proper alignment and focus.

The eye is a remarkable organ that allows us to perceive and interact with our surroundings. Various medical specialties, such as ophthalmology and optometry, are dedicated to the diagnosis, treatment, and management of various eye conditions and diseases.

Vision tests are a series of procedures used to assess various aspects of the visual system, including visual acuity, accommodation, convergence, divergence, stereopsis, color vision, and peripheral vision. These tests help healthcare professionals diagnose and manage vision disorders, such as nearsightedness, farsightedness, astigmatism, amblyopia, strabismus, and eye diseases like glaucoma, cataracts, and macular degeneration. Common vision tests include:

1. Visual acuity test (Snellen chart or letter chart): Measures the sharpness of a person's vision at different distances.
2. Refraction test: Determines the correct lens prescription for glasses or contact lenses by assessing how light is bent as it passes through the eye.
3. Color vision test: Evaluates the ability to distinguish between different colors and color combinations, often using pseudoisochromatic plates or Ishihara tests.
4. Stereopsis test: Assesses depth perception and binocular vision by presenting separate images to each eye that, when combined, create a three-dimensional effect.
5. Cover test: Examines eye alignment and the presence of strabismus (crossed eyes or turned eyes) by covering and uncovering each eye while observing eye movements.
6. Ocular motility test: Assesses the ability to move the eyes in various directions and coordinate both eyes during tracking and convergence/divergence movements.
7. Accommodation test: Evaluates the ability to focus on objects at different distances by using lenses, prisms, or dynamic retinoscopy.
8. Pupillary response test: Examines the size and reaction of the pupils to light and near objects.
9. Visual field test: Measures the peripheral (side) vision using automated perimetry or manual confrontation techniques.
10. Slit-lamp examination: Inspects the structures of the front part of the eye, such as the cornea, iris, lens, and anterior chamber, using a specialized microscope.

These tests are typically performed by optometrists, ophthalmologists, or other vision care professionals during routine eye examinations or when visual symptoms are present.

Myxedema is not a term used in modern medicine to describe a specific medical condition. However, historically, it was used to refer to the severe form of hypothyroidism, a condition characterized by an underactive thyroid gland that doesn't produce enough thyroid hormones. In hypothyroidism, various body functions slow down, which can lead to symptoms such as fatigue, weight gain, cold intolerance, constipation, and dry skin.

Myxedema specifically refers to the physical signs of severe hypothyroidism, including swelling (edema) and thickening of the skin, particularly around the face, hands, and feet, as well as a puffy appearance of the face. The term myxedema coma was used to describe a rare but life-threatening complication of long-standing, untreated hypothyroidism, characterized by altered mental status, hypothermia, and other systemic manifestations.

Nowadays, healthcare professionals use more precise medical terminology to describe these conditions, such as hypothyroidism or myxedematous edema, rather than the outdated term myxedema.

Thyroiditis is a general term that refers to inflammation of the thyroid gland. It can be caused by various factors such as infections, autoimmune disorders, or medications. Depending on the cause and severity, thyroiditis may lead to overproduction (hyperthyroidism) or underproduction (hypothyroidism) of thyroid hormones, or it can result in a temporary or permanent loss of thyroid function.

There are several types of thyroiditis, including:

1. Hashimoto's thyroiditis - an autoimmune disorder where the body attacks and damages the thyroid gland, leading to hypothyroidism.
2. Subacute granulomatous thyroiditis (De Quervain's thyroiditis) - often follows a viral infection and results in painful inflammation of the thyroid gland, causing hyperthyroidism followed by hypothyroidism.
3. Silent thyroiditis - an autoimmune disorder similar to Hashimoto's thyroiditis but without symptoms like pain or tenderness; it can cause temporary hyperthyroidism and later hypothyroidism.
4. Postpartum thyroiditis - occurs in women after childbirth, causing inflammation of the thyroid gland leading to hyperthyroidism followed by hypothyroidism.
5. Acute suppurative thyroiditis - a rare bacterial infection that causes painful swelling and redness of the thyroid gland, usually requiring antibiotics for treatment.

Symptoms of thyroiditis depend on whether it leads to hyperthyroidism or hypothyroidism. Hyperthyroidism symptoms include rapid heartbeat, weight loss, heat intolerance, anxiety, and tremors. Hypothyroidism symptoms include fatigue, weight gain, cold intolerance, constipation, dry skin, and depression. Treatment varies depending on the type of thyroiditis and its severity.

Hashimoto's disease, also known as chronic lymphocytic thyroiditis, is an autoimmune disorder in which the immune system mistakenly attacks and damages the thyroid gland. The resulting inflammation often leads to an underactive thyroid gland (hypothyroidism). It primarily affects middle-aged women but can also occur in men and women of any age and in children.

The exact cause of Hashimoto's disease is unclear, but it appears to involve interactions between genetic and environmental factors. The disorder tends to run in families, and having a family member with Hashimoto's disease or another autoimmune disorder increases the risk.

Symptoms of hypothyroidism include fatigue, weight gain, constipation, cold intolerance, joint and muscle pain, dry skin, thinning hair, irregular menstrual periods, and depression. However, some people with Hashimoto's disease may have no symptoms for many years.

Diagnosis is typically based on a combination of symptoms, physical examination findings, and laboratory test results. Treatment usually involves thyroid hormone replacement therapy, which can help manage symptoms and prevent complications of hypothyroidism. Regular monitoring of thyroid function is necessary to adjust the dosage of medication as needed.

Glucocorticoids are a class of steroid hormones that are naturally produced in the adrenal gland, or can be synthetically manufactured. They play an essential role in the metabolism of carbohydrates, proteins, and fats, and have significant anti-inflammatory effects. Glucocorticoids suppress immune responses and inflammation by inhibiting the release of inflammatory mediators from various cells, such as mast cells, eosinophils, and lymphocytes. They are frequently used in medical treatment for a wide range of conditions, including allergies, asthma, rheumatoid arthritis, dermatological disorders, and certain cancers. Prolonged use or high doses of glucocorticoids can lead to several side effects, such as weight gain, mood changes, osteoporosis, and increased susceptibility to infections.

Visual acuity is a measure of the sharpness or clarity of vision. It is usually tested by reading an eye chart from a specific distance, such as 20 feet (6 meters). The standard eye chart used for this purpose is called the Snellen chart, which contains rows of letters that decrease in size as you read down the chart.

Visual acuity is typically expressed as a fraction, with the numerator representing the testing distance and the denominator indicating the smallest line of type that can be read clearly. For example, if a person can read the line on the eye chart that corresponds to a visual acuity of 20/20, it means they have normal vision at 20 feet. If their visual acuity is 20/40, it means they must be as close as 20 feet to see what someone with normal vision can see at 40 feet.

It's important to note that visual acuity is just one aspect of overall vision and does not necessarily reflect other important factors such as peripheral vision, depth perception, color vision, or contrast sensitivity.

Of patients with Graves' hyperthyroidism, 20 to 25 percent have clinically obvious Graves' ophthalmopathy, while only 3-5% will ... Infiltrative ophthalmopathy Exophthalmos Bahn RS (February 2010). "Graves' ophthalmopathy". The New England Journal of Medicine ... ophthalmopathy (orbitopathy)". UpToDate. Bartalena L, Marcocci C, Pinchera A (April 2002). "Graves' ophthalmopathy: a ... Graves' ophthalmopathy may occur before, with, or after the onset of overt thyroid disease and usually has a slow onset over ...
It may be seen in many conditions like Graves' ophthalmopathy, Orbital cellulitis, Orbital pseudotumor etc. A weak bell ... Bahn, Rebecca S. (2010). "Graves' Ophthalmopathy". New England Journal of Medicine. 362 (8): 726-38. doi:10.1056/NEJMra0905750 ...
... and Graves' Ophthalmopathy. Thyroid. Mary Ann Liebert, Inc. (American Thyroid Association (ATA)). 21 (12): 1359-1366. doi: ... Graves disease may occur before or after the development of autoimmune thyroiditis. Patients may also have coexisting ... Many patients report a family history of autoimmune thyroiditis or Graves disease. Twin studies have revealed a concordance of ... McLachlan, Sandra; Alpi, Kristine; Rapoport, Basil (2011). "Review and Hypothesis: Does Graves' Disease Develop in Non-Human ...
Understanding Graves' Ophthalmopathy. Trafford Publishing. pp. 32-. ISBN 978-1-4120-0911-9. Retrieved 30 April 2012. (Articles ... ". "Ballet's sign": Palsy affecting one or more extraocular muscles, commonly associated with Graves' ophthalmopathy. A ...
It is found in Graves' ophthalmopathy.[citation needed] Von Graefe's sign Boston's sign Sarkar, Phani Kumar; Sarkar, Pradip; ... Acharjee, Umakanta; Halder, Soumya; Sarkar, Sandip; Noatia, Chiranjit (30 June 2014). "Graves' ophthalmopathy in a euthyroid ...
Graves ophthalmopathy Graves orbitopathy Cline D; Hofstetter HW; Griffin JR. Dictionary of Visual Science. 4th ed. Butterworth- ... Dalrymple's sign is a widened palpebral (eyelid) opening, or eyelid spasm, seen in thyrotoxicosis (as seen in Graves' disease, ... Other eye signs described within the symptomology of Graves' disease are Stellwag's sign (rare blinking), Rosenbach's sign ( ...
Graves' ophthalmopathy IgG4-related ophthalmic disease Gleason JE. Idipathic myositis involving the extraocular muscles. ... A differential diagnosis includes lymphoproliferative lesions, thyroid ophthalmopathy, IgG4-related ophthalmic disease, ... IOI or orbital pseudotumor is the second most common cause of exophthalmos following Grave's orbitopathy and the third most ...
Witte, A; Landgraf, R; Markl, A; Boergen, KP; Hasenfratz, G; Pickardt, CR (1 October 1985). "Treatment of Graves' ... ophthalmopathy with cyclosporin A.". Klinische Wochenschrift. 63 (19): 1000-4. doi:10.1007/BF01737636. PMID 3840854. S2CID ... of scientific conferences and published more than 80 papers and several books on thyroid disorders and endocrine ophthalmopathy ...
TRAbs are also useful in the diagnosis of Graves' ophthalmopathy. Although the exact mechanism of how TRAbs induce Graves' ... During treatment of Graves' disease they may also become the predominant antibody, which can cause hypothyroidism. The clinical ... Graves' disease and Hashimoto's thyroiditis are commonly associated with the presence of anti-thyroid autoantibodies. Although ... The production of antibodies in Graves' disease is thought to arise by activation of CD4+ T-cells, followed by B-cell ...
... it is associated with other manifestations of Graves' disease, such as Graves' ophthalmopathy and thyroid dermopathy. ... dermopathy and acropachy are markers of severe Graves' ophthalmopathy". Thyroid. 13 (12): 1141-4. doi:10.1089/10507250360731541 ... Acropachy is a dermopathy associated with Graves' disease. It is characterized by soft-tissue swelling of the hands and ... Fatourechi V, Bartley GB, Eghbali-Fatourechi GZ, Powell CC, Ahmed DD, Garrity JA (December 2003). "Graves' ...
Graves disease may also cause axial protrusion of the eye, known as Graves' ophthalmopathy, due to buildup of extracellular ... Development of Graves' ophthalmopathy may be independent of thyroid function. Orbita Medial wall of left orbit Dissection ... Hatton, M. P.; Rubin, P. A. (2002). "The pathophysiology of thyroid-associated ophthalmopathy". Ophthalmol Clin North Am. 15 (1 ...
Inflammatory/Infection: Graves' ophthalmopathy due to Graves' disease, usually causes bilateral proptosis. Orbital cellulitis ... Exophthalmos can be either bilateral (as is often seen in Graves' disease) or unilateral (as is often seen in an orbital tumor ... In the case of Graves' disease, the displacement of the eye results from abnormal connective tissue deposition in the orbit and ... The term exophthalmos is often used when describing proptosis associated with Graves' disease. Exophthalmos is commonly found ...
Numerous additional signs can be found for Graves disease under Graves' ophthalmopathy. Medical eponyms Pathognomonic List of ...
Fakhri, O (1991). The use of low voltage electric current in the treatment of "Graves Ophthalmopathy." International ...
2010). "Disease association of the CD103 polymorphisms in Taiwan Chinese Graves' ophthalmopathy patients". Ophthalmology. 117 ( ...
Somatostatin receptor genes expression and effects of octreotide on orbital fibroblasts from Graves' ophthalmopathy]". Minerva ... "Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease". The Journal of Clinical ...
Somatostatin receptor genes expression and effects of octreotide on orbital fibroblasts from Graves' ophthalmopathy]". Minerva ...
Somatostatin receptor genes expression and effects of octreotide on orbital fibroblasts from Graves' ophthalmopathy]". Minerva ... "Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease". The Journal of Clinical ...
May 2018). "Graves' ophthalmopathy: low-dose dexamethasone reduces retinoic acid receptor-alpha gene expression in orbital ... In the thyroid disorder known as Graves' ophthalmopathy, inflammation and fat accumulation in the orbitonasal region cause ...
2002). "[Somatostatin receptor genes expression and effects of octreotide on orbital fibroblasts from Graves' ophthalmopathy ...
However, these need to be distinguished from Graves' ophthalmopathy, which can only occur in patients who have Graves' disease ... of patients with Graves' disease will suffer from clinically obvious Graves' ophthalmopathy, and not just from the eye signs of ... It is estimated that for every 100,000 persons, 16 women and 3 men have Graves' ophthalmopathy every year. Although it is true ... Graves' ophthalmopathy (protrusion of one or both eyes) Pretibial myxedema Cardiovascular features may include hypertension, ...
"Hypoxia-Dependent HIF-1 Activation Impacts on Tissue Remodeling in Graves' Ophthalmopathy-Implications for Smoking". The ...
Increased expression of leiomodin 1 may be linked to Graves' disease and thyroid-associated ophthalmopathy. [provided by RefSeq ...
Distinctive clinical features of Graves' disease include the presence of ophthalmopathy, diffuse goitre and pretibial myxoedema ... Hyperthyroidism due to Graves' disease may worsen in the first trimester of pregnancy, remit in later pregnancy, and ... Most cases are due to Graves' disease although less common causes (e.g. toxic nodules and thyroiditis) may be seen. Clinical ... Rarely neonatal hypothyroidism may also be observed in the infants of mothers with Graves' hyperthyroidism. This may result ...
Gorman CA (June 1998). "The measurement of change in Graves' ophthalmopathy". Thyroid. 8 (6): 539-43. doi:10.1089/thy.1998.8. ... Graves' disease occurs in about 0.5% of people. Graves' disease data has shown that the lifetime risk for women is around 3% ... Feldon SE, Muramatsu S, Weiner JM (October 1984). "Clinical classification of Graves' ophthalmopathy. Identification of risk ... "Graves Disease". www.niddk.nih.gov. August 10, 2012. Archived from the original on April 2, 2015. Retrieved 2015-04-02. "Graves ...
Feldman suffered from thyroid disease and developed Graves' ophthalmopathy, causing his eyes to protrude and become misaligned ...
In a multicenter, randomized trial in patients with active Graves' ophthalmopathy, teprotumumab was more effective than placebo ...
"A genomic point mutation in the extracellular domain of the thyrotropin receptor in patients with Graves' ophthalmopathy". The ... Graves PN, Tomer Y, Davies TF (Sep 1992). "Cloning and sequencing of a 1.3 KB variant of human thyrotropin receptor mRNA ... The latter explains the reason of the myxedema finding during Graves disease. In addition, it has also been found to be ... Graves' disease GRCh38: Ensembl release 89: ENSG00000165409 - Ensembl, May 2017 GRCm38: Ensembl release 89: ENSMUSG00000020963 ...
Two small studies found tocilizumab to be beneficial in endocrine ophthalmopathy (Graves' orbitopathy) that is refractory to ... November 2018). "Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A ... August 2020). "Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 ...
In addition, gradual protrusion of the eyes may occur, called Graves' ophthalmopathy, as may swelling of the front of the shins ... Graves' disease was described by Robert James Graves in 1834. The role of the thyroid gland in metabolism was demonstrated in ... Graves' disease is an autoimmune disorder that is the most common cause of hyperthyroidism. In Graves' disease, for an unknown ... Graves' disease can be diagnosed by the presence of pathomnomonic features such as involvement of the eyes and shins, or ...
  • In fact, upper eyelid retraction is the most common ocular sign of Graves' orbitopathy. (wikipedia.org)
  • Time to review the descriptions and eponymythology of the forgotten signs associated with Graves orbitopathy - the signs of Dalrymple, Stellwag, von Graefe, Möbius and Joffroy. (litfl.com)
  • Orbitopathy associated with Graves disease may severely compromise a patient's vision. (medscape.com)
  • Patients with Graves orbitopathy usually have hyperthyroidism but can have euthyroidism or hypothyroidism . (medscape.com)
  • Graves' disease (GD) and Graves' orbitopathy (GO) result from ongoing stimulation of the TSH receptor due to autoantibodies acting as persistent agonists. (frontiersin.org)
  • GD is the most common form of hyperthyroidism ( 1 ) and up to 40% [CI 0.32 - 0.48] of GD patients have clinically apparent abnormalities of orbit soft tissue, known as Graves' orbitopathy (GO) or thyroid eye disease (TED) ( 2 ). (frontiersin.org)
  • Graves ophthalmopathy (also known as Graves orbitopathy) is shown below. (medscape.com)
  • A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves orbitopathy. (thieme-connect.de)
  • TED is sometimes called Graves' orbitopathy or Graves' ophthalmopathy. (healthline.com)
  • Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease. (healthline.com)
  • Orbitopathy is the main extra thyroidal manifestation of Graves' disease. (minervamedica.it)
  • An accurate diagnostic assessment is required, in order to plan an adequate treatment of Graves' orbitopathy. (minervamedica.it)
  • Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor. (uni-due.de)
  • Thyroid eye disease, also known as Graves' orbitopathy or Graves' ophthalmopathy, is an eye condition that happens in a person with an overactive thyroid. (medicinenet.com)
  • Graves' orbitopathy (GO) is the main extrathyroidal manifestation of GD, potentially involving autoimmunity against the IGF1 receptor (IGF1R: We tested for autoantibodies against the IGF1R (IGF1R-Abs) in sera of GD patients and controls and elucidated their possible implication in the disease. (thyroidmanager.org)
  • Approximately half the patients with GD have ocular involvement, Graves' orbitopathy. (standardofcare.com)
  • Eye lid retraction, exophthalmos , extraocular muscle dysfunction, and ocular pain arethe most common manifestations of graves orbitopathy. (standardofcare.com)
  • Orbital decompression is widely performed for the management of proptosis for cosmetic and functional cases of Graves orbitopathy. (bvsalud.org)
  • PURPOSE: The purpose of the study was to measure the effect of rim-off deep lateral decompression for Graves orbitopathy on the lateral rectus muscle path and oculomotor balance. (bvsalud.org)
  • There is no real agreement as to what we should do with smokers, because we know that they have an increased risk of developing Graves orbitopathy. (medscape.com)
  • All patients with regarding the pathogenesis, pathophysio- confirmed diagnosis of Graves disease logy, and management of this disease attending the endocrine clinics of the [ 6,7 ]. (who.int)
  • The demonstration in fibroblasts of RNA encoding this important autoantigen in Graves' disease suggests that the TSH receptor might play a role in the pathogenesis of the connective tissue manifestations of this disease. (elsevierpure.com)
  • Current insights into the pathogenesis of Graves ophthalmopathy. (thieme-connect.de)
  • A family history of thyroid dysfunction is found in approximately half the patients with Graves' disease and the pathogenesis is strongly influenced by genetics. (standardofcare.com)
  • The pathogenesis of infiltrative ophthalmopathy (responsible for the exophthalmos in Graves disease) is poorly understood but may result from immunoglobulins directed to the TSH receptors in the orbital fibroblasts and fat that result in release of proinflammatory cytokines, inflammation, and accumulation of glycosaminoglycans. (msdmanuals.com)
  • BACKGROUND: TSH receptor autoantibodies (TRAbs) are pathognomonic for Graves' disease and are thought to also underly the pathogenesis of Graves' ophthalmopathy (GO). (bvsalud.org)
  • Fibroblasts are target cells for the autoimmune process in Graves' ophthalmopathy and pretibial dermopathy. (elsevierpure.com)
  • A small percentage of people with Graves' disease develop a skin abnormality called pretibial myxedema or Graves' dermopathy. (medlineplus.gov)
  • Graves' ophthalmopathy, thyroid dermopathy, and hyperthyroidism arise from a single underlying systemic process with variable expression. (standardofcare.com)
  • Because the autoantigen involved in the hyperthyroidism of Graves' disease is the TSH receptor, we sought to determine whether RNA encoding this receptor might be present in retroocular and pretibial fibroblasts. (elsevierpure.com)
  • Studies suggest that immune system abnormalities also underlie Graves' ophthalmopathy and pretibial myxedema. (medlineplus.gov)
  • Only 5-6% of patients with Graves disease develop problems severe enough to warrant surgical decompression on a functional basis. (medscape.com)
  • In its most involved forms, the ophthalmopathy can result in severe corneal problems that necessitate decompression. (medscape.com)
  • Various approaches have been described since surgical decompression of the orbit for thyroid ophthalmopathy was initially advocated in 1911. (medscape.com)
  • AIM: To evaluate the long-term results of different orbital decompression techniques performed in patients with Graves' ophthalmopathy (GO). (gazi.edu.tr)
  • RÉSUMÉ Cette étude a évalué la prévalence et la gravité des manifestations ophtalmologiques chez les patients atteints de la maladie de Graves-Basedow (n = 68) qui se sont présentés au service de consultations externes d'endocrinologie de l'Université des Sciences médicales de Mashad entre décembre 2002 et septembre 2005. (who.int)
  • Varying degrees of manifestations of Graves ophthalmopathy. (medscape.com)
  • There have been few studies to evaluate with Graves disease will develop GO and the prevalence and severity of GO in Iranian severe forms affect 3% to 5% of patients. (who.int)
  • The onset of the ophthalmopathy is in aimed to investigate the prevalence and most cases concomitant with the onset severity of ophthalmopathy in Graves of hyperthyroidism, but eye disease may patients in our area (north-east of the precede or follow hyperthyroidism [ 3 ]. (who.int)
  • Purpose: To assess the effect of etanercept, an antitumour necrosis factor (anti-TNF) drug, on clinical signs in Graves' ophthalmopathy (GO).MethodsA total of 10 consecutive patients (seven female, three male) with recent-onset, active, mildly-to-moderately severe GO were treated with subcutaneous injections of 25mg etanercept (Enbrel®) twice weekly during 12 weeks. (eur.nl)
  • Aims To explore the role of the suppressor of cytokine signalling 3 (SOCS3) gene in Graves' ophthalmopathy (GO) patients. (bmj.com)
  • Methods A case-control study was conducted in a Chinese Han population by recruiting 114 Graves' disease (GD) patients with GO and 156 GD patients without GO. (bmj.com)
  • Methods: GD patients without ophthalmopathy or previous treatment with radioiodine were prospectively included at treatment with radioiodine for hyperthyroidism. (lu.se)
  • Joffroy sign (1893): absent wrinkling of the forehead when a patient in patients Graves Ophthalmopathy looks up with the head bent forwards. (litfl.com)
  • Graves Ophthalmopathy: constellation of findings, apparent in 25-50% of patients with Graves disease. (litfl.com)
  • Graves' ophthalmopathy is the most common extra-thyroid manifestation in patients with Graves' disease, based on inflammatory and autoimmune conditions in orbital tissue. (ui.ac.id)
  • Approximately half of all patients with Graves hyperthyroidism develop ophthalmopathy. (medscape.com)
  • Background: Graves' ophthalmopathy (GO) is an autoimmune manifestation of orbit affecting approximately 25% of patients with Graves' disease (GD). (unict.it)
  • TED is most common in people with hyperthyroidism due to Graves' disease and rarely, may occur in patients with normal or low thyroid levels. (thyroid.org)
  • Dr. Stan's research aims to improve patients' quality of life after therapy with radioactive iodine for Graves' disease. (mayo.edu)
  • He and his colleagues also hope to offer patients more treatment options for Graves' ophthalmopathy, which is currently a condition without good therapy options. (mayo.edu)
  • In some patients, Graves disease represents a part of more extensive autoimmune processes leading to dysfunction of multiple organs (eg, polyglandular autoimmune syndromes ). (medscape.com)
  • Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves ophthalmopathy. (thieme-connect.de)
  • The influence of radioiodine therapy on ocular changes and their relation to urine cotinine level in patients with Graves' Ophthalmopathy. (nel.edu)
  • Radioiodine therapy (RIT) is frequently used as the definitive treatment in patients with Graves' hyperthyroidism when remissi. (nel.edu)
  • In order to investigate the relationship between Graves disease, its associated ophthalmopathy and smoking, we followed retrospectively a group of 270 patients with Graves disease (233 females and 37 males). (endocrine-abstracts.org)
  • Critically important Graves disease occurs in 25% of patients, however sub clinical involvement with extreme ocular muscle enlargement is seen radiographically it up to 70% of patients. (standardofcare.com)
  • Graves' ophthalmopathy is potentially sight threatening eye disease generally occurring in patients with hyperthyroidism or a history of hyperthyroidism due to Graves' disease . (standardofcare.com)
  • Graves' ophthalmopathy, also known as thyroid-associated ophthalmopathy or thyroid eye disease may sometimes occur in patients with euthyroid or hypothyroid chronic autoimmune thyroiditis. (standardofcare.com)
  • If possible in patients with mild progressive ophthalmopathy, institute a course of steroids (prednisone up to 1 mg/kg) for 2-3 months, tapering a few days before radioiodine therapy. (medscape.com)
  • In patients with severe Graves ophthalmopathy, treatment of hyperthyroidism and ophthalmopathy should proceed concurrently and independently of each other. (medscape.com)
  • The included patients were asked to complete the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) before strabismus surgery and 6 weeks after the surgery, respectively. (bvsalud.org)
  • Severe ophthalmopathy is an uncommon but problematic manifestation of Graves disease. (medscape.com)
  • Graves' ophthalmopathy, also known as Graves' eye disease, represents the most frequent non-thyroidal manifestation of. (advancedreconstruction.com)
  • A study published in 2022 reported that about 90 percent of thyroid eye disease is associated with Graves' disease and requires multispeciality collaboration, including ophthalmology, endocrinology, and otolaryngology, because Graves' involves different systems of the body. (everydayhealth.com)
  • Graves' ophthalmopathy , also called thyroid eye disease, is an autoimmune disease that can occur in people with Graves' disease. (healthwise.net)
  • Graves disease: Autoimmune disease that affects the thyroid. (litfl.com)
  • Graves' disease (GD), characterized by TSH-receptor stimulating antibodies and increased thyroid hormone serum levels, is an autoimmune disease affecting roughly 3% of the general population ( 1 ). (frontiersin.org)
  • The most common cause of TED is Graves' disease, an autoimmune disease where the immune system attacks the thyroid gland and causes it to become overactive. (healthline.com)
  • Thyroid-associated ophthalmopathy (TAO) is an autoimmune disease involving the ocular tissues that may require strabismus surgery treatment. (bvsalud.org)
  • Thyroid eye disease (TED) has been viewed as a phenomenon seen in Graves disease of the thyroid, but it's now recognized as a separate autoimmune disease. (medscape.com)
  • Graves' ophthalmopathy, also known as thyroid eye disease (TED), is an autoimmune inflammatory disorder of the orbit and periorbital tissues, characterized by upper eyelid retraction, lid lag, swelling, redness (erythema), conjunctivitis, and bulging eyes (exophthalmos). (wikipedia.org)
  • Graves disease, originally called Graves-Basedow disease, was first described as the triad of hyperthyroidism , goiter , and exophthalmos in 1835. (medscape.com)
  • Transient periods of thyrotoxicosis sometimes occur, and rarely full hyperthyroid Graves' disease with active ophthalmopathy. (igi-global.com)
  • Graves thyrotoxicosis frequently occurs after delivery through immune rebound mechanism. (endocrine-abstracts.org)
  • In the United States and the United Kingdom, the most common reason for having thyrotoxicosis is hyperthyroidism from Graves disease , a condition caused by antibodies to the thyroid gland. (medscape.com)
  • It occurs most commonly in individuals with Graves' disease, and less commonly in individuals with Hashimoto's thyroiditis, or in those who are euthyroid. (wikipedia.org)
  • Graves disease , along with Hashimoto thyroiditis , is classified as an autoimmune thyroid disorder . (medscape.com)
  • [ 2 ] Moreover, advances in cancer immunotherapy with immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies) have led to immune-related adverse effects, including problems affecting the thyroid glands (ie, thyroiditis [typically with a transient hyperthyroid phase followed by a permanent hypothyroid phase] and Graves disease). (medscape.com)
  • This practical guideline was formed by a multidiciplinary team, and is intended to provide guidance for diagnosis and management of Graves' ophthalmopathy in daily clinical practice to improve quality of care and treatment outcome. (ui.ac.id)
  • The most common clinical features of Graves' ophthalomopathy are upper eyelid retraction, edema, erythema of the periorbital tissues and conjunctiva and propptosis. (standardofcare.com)
  • Ophthalmopathy may also occur before the onset of hyperthyroidism or as late as 20 years afterward and frequently worsens or abates independently of the clinical course of hyperthyroidism. (msdmanuals.com)
  • In January 2020, the US Food and Drug Administration approved teprotumumab-trbw for the treatment of Graves' ophthalmopathy. (wikipedia.org)
  • In Graves' ophthalmopathy, the tissues and muscles behind the eyes become swollen. (healthwise.net)
  • Graves' disease is classified as an autoimmune disorder, one of a large group of conditions that occur when the immune system attacks the body's own tissues and organs. (medlineplus.gov)
  • In Graves' ophthalmopathy, the immune system attacks the tissues and muscles surrounding the eyes, resulting in inflammation that produces a bulging-eye effect. (healthline.com)
  • Thyrotropin receptors in orbital tissues such as fibroblasts and adipocytes are the targets of such antobodies and cause the ophthalmopathy. (standardofcare.com)
  • The age-adjusted incidence severity of ophthalmopathy. (who.int)
  • Thyrotropin receptor autoantibodies are independent risk factors for Graves ophthalmopathy and help to predict severity and outcome of the disease. (thieme-connect.de)
  • Graves' ophthalmopathy annual adjusted incidence rate of 16 women and three men per 100,000 population (Bartley GB). (standardofcare.com)
  • The mean ophthalmopathy index (OI) prior to treatment was 5.8, at 6 weeks 4.8, and at 12 weeks 4.4. (eur.nl)
  • Introduction: Treatment of Graves´ disease (GD) with radioiodine increases the risk of developing Graves´ ophthalmopathy (GO), and the link between thyroid and orbital tissue may be the presence of TSH-receptors. (lu.se)
  • Assessment of a carcinogenic risk for treatment of Graves' ophthalmopathy in dependence on age and irradiation geometry. (nih.gov)
  • Thyroid eye disease may happen in a person months before the diagnosis of an overactive thyroid or after receiving treatment for Graves' disease affecting the thyroid. (medicinenet.com)
  • The aim of the study was to compare the effectiveness of TTx to other treatment modalities of Graves' disease and examine whether the lowering of TRAbs is associated with GO improvements. (bvsalud.org)
  • About one in every three people with Graves' disease develop eye symptoms. (thyroid.org)
  • In people with Graves' disease, the thyroid is overactive and makes more hormones than the body needs. (medlineplus.gov)
  • Some people with Graves' disease develop an enlargement of the thyroid called a goiter. (medlineplus.gov)
  • Between 25 and 50 percent of people with Graves' disease have eye abnormalities, which are known as Graves' ophthalmopathy. (medlineplus.gov)
  • In people with Graves' disease, the immune system creates a protein (antibody) called thyroid-stimulating immunoglobulin (TSI). (medlineplus.gov)
  • People with Graves' disease have an increased risk of developing other autoimmune disorders, including rheumatoid arthritis , pernicious anemia, systemic lupus erythematosus , Addison disease, celiac disease , type 1 diabetes , and vitiligo . (medlineplus.gov)
  • The National Institutes of Health estimate one-third of people with Graves' disease also develop an eye condition called Graves' ophthalmopathy. (healthline.com)
  • Severe cases of ophthalmopathy may be associated with lid edema, chemosis (edema of the conjunctiva), and diminished ocular motility. (medscape.com)
  • Conclusion: Severe unilateral, mono-muscular GO in a euthyroid Graves' patient was found to be sustained by rapid and massive fibrosis of the inferior rectus muscle of the right orbit. (unict.it)
  • No matter what stage - mild, moderate, or severe - your disease is in, "If someone has Graves', they should be seeing an ophthalmologist to get a baseline eye exam," says Madina Falcone, MD , director of oculoplastics and orbital surgery at University of Connecticut Health in Farmington. (everydayhealth.com)
  • Graves' ophthalmopathy associated with periorbital and retro-orbital inflammation of fat, muscle, and connective tissue. (standardofcare.com)
  • Graves disease is an autoimmune disorder characterized by hyperthyroidism due to circulating autoantibodies. (medscape.com)
  • Although Graves' disease may affect anyone, it is more common among women and has an onset before the age of 40 years. (standardofcare.com)
  • While eye symptoms can occur at any time, they usually appear within the first year of diagnosis of Graves' disease. (thyroid.org)
  • These doctors and experts can help treat the symptoms of thyroid eye disease (Graves' ophthalmopathy). (everydayhealth.com)
  • The foods you eat can't cure you of Graves' disease, but some nutrients that may help relieve symptoms or reduce flares. (healthline.com)
  • In Graves disease, the radioactive iodine uptake is increased, and the uptake is diffusely distributed over the entire gland. (medscape.com)
  • In order to establish the diagnosis, the guidelines recommend that we measure thyroid-stimulating hormone (TSH) receptor antibodies (the causative problem in Graves disease), do radioactive iodine uptake, or do an ultrasound scan. (medscape.com)
  • One concern with the use of radioiodine in persons with Graves disease is its controversial potential for exacerbating existing Graves ophthalmopathy. (medscape.com)
  • There is a close association between levels of TSH binding inhibitory immunoglobulins (TBIIs) and Graves' ophthalmopathy (GO). (thyroidmanager.org)
  • Variations in many genes have been studied as possible risk factors for Graves' disease. (medlineplus.gov)
  • Other genes that have been associated with Graves' disease help regulate the immune system or are involved in normal thyroid function. (medlineplus.gov)
  • Heredity increases the risk of Graves disease, although the genes involved are unknown. (msdmanuals.com)
  • Graves' disease is an autoimmune condition that results in hyperthyroidism , or an overactive thyroid. (healthline.com)
  • Thyroid eye disease is caused by Graves' disease, an autoimmune condition in which the body's immune cells cause the tissue around and behind the eyes to grow. (medicinenet.com)
  • This condition that can be quite debilitating and is caused by the antibodies that cause Graves disease. (medscape.com)
  • The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves disease identifies a group at markedly increased risk of ophthalmopathy. (thieme-connect.de)
  • Graves disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies. (thieme-connect.de)
  • Graves' disease (GD) is maintained by stimulating antibodies against the TSH receptor. (thyroidmanager.org)
  • Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves disease immunoglobins. (thieme-connect.de)
  • Excessive orbital fibroblast proliferation and hyaluronan production are characteristic of Graves' ophthalmopathy (GO) and are driven by local mediators. (eur.nl)
  • Other common ocular disorders, such as retinal ischemia, anterior ischemic optic neuropathy, and Graves ophthalmopathy, are also significantly linked to this harmful habit. (nih.gov)
  • Graves' ophthalmopathy may get worse if your thyroid levels are out of balance. (healthwise.net)
  • Smoking increases your chances of developing Graves' ophthalmopathy. (healthwise.net)
  • Receiving iodine therapy for Graves' disease increases the risk of thyroid eye disease. (medicinenet.com)
  • Squamous cell carcinoma of the eyelid masquerading as 'malignant' ophthalmopathy of Graves's disease. (bmj.com)
  • For those with no obvious ophthalmopathy, the chances of exacerbation are much lower. (medscape.com)
  • The most commonly used therapy for Graves disease is radioactive iodine. (medscape.com)

No images available that match "graves ophthalmopathy"